All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-10-16T10:08:00.000Z

Is there an optimal time to deploy immunotherapies in multiple myeloma?

Oct 16, 2020
Share:

Bookmark this article

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Meral Beksaç, Ankara University School of Medicine, Ankara, TR, about immunotherapy for MM. We asked, Is there an optimal time to deploy immunotherapies in multiple myeloma?

Is there an optimal time to deploy immunotherapies in multiple myeloma?

In this video, Meral Beksaç talks about how the field of immunotherapy has been advancing rapidly in recent years, with novel monoclonal antibodies (mAbs), alone or with drug conjugates, being developed for use at diagnosis and relapse. Patients today can benefit from the use of anti-CD38 mAbs alongside chemotherapy, whether they are eligible for transplant or not. High rates of measurable residual disease negativity can be achieved by using these treatments.

Figure 1. New ESMO guidelines proposal for the treatment of relapsed multiple myeloma, presented by Meral Beksaç at EBMT 2020, courtesy of María-Victoria Mateos.1

Ab, antibody; CAR, chimeric antigen receptor; dara, daratumumab, dex, dexamethasone; IMiD, immunomodulatory imide drug; PI, proteasome inhibitor; pom, pomalidomide. 

  1. Beksaç M. How should we position immunotherapies in the changing paradigm of myeloma treatment? 46th Annual Meeting of the EBMT; Sep 1, 2020; Virtual.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox